NeuroSense Therapeutics Ltd [NASDAQ: NRSN] stock went on a downward path that fall over -10.50% on Thursday, amounting to a one-week price decrease of less than -16.05%.
Over the last 12 months, NRSN stock dropped by -46.03%. The one-year NeuroSense Therapeutics Ltd stock forecast points to a potential upside of 87.05. The average equity rating for NRSN stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $12.27 million, with 15.38 million shares outstanding and 13.11 million shares in the current float. Compared to the average trading volume of 233.25K shares, NRSN stock reached a trading volume of 4061285 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on NeuroSense Therapeutics Ltd [NRSN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NRSN shares is $5.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NRSN stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
NRSN Stock Performance Analysis:
NeuroSense Therapeutics Ltd [NRSN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.05. With this latest performance, NRSN shares dropped by -45.16% in over the last four-week period, additionally sinking by -45.60% over the last 6 months – not to mention a drop of -46.03% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NRSN stock in for the last two-week period is set at 34.64, with the RSI for the last a single of trading hit 31.23, and the three-weeks RSI is set at 36.75 for NeuroSense Therapeutics Ltd [NRSN]. The present Moving Average for the last 50 days of trading for this stock 0.9857, while it was recorded at 0.7483 for the last single week of trading, and 1.0961 for the last 200 days.
Insight into NeuroSense Therapeutics Ltd Fundamentals:
NeuroSense Therapeutics Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.26 and a Current Ratio set at 0.26.
NeuroSense Therapeutics Ltd [NRSN] Institutonal Ownership Details
The top three institutional holders of NRSN stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in NRSN stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in NRSN stock with ownership which is approximately 5.1238%.
